Pazopanib: a novel treatment option for aggressive fibromatosis

BACKGROUND: Aggressive fibromatosis (AF), also known as desmoid tumor, is an uncommon soft tissue neoplasm. AF does not metastasize, but it is locally invasive and its propensity for recurrence after conservative resection is well documented. No effective cytotoxic treatment has been reported, hence...

Descripción completa

Detalles Bibliográficos
Autores principales: Bulut, Gulcan, Ozluk, Anil, Erdogan, Atike Pınar, Uslu, Ruchan, Elmas, Nevra, Karaca, Burcak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131445/
https://www.ncbi.nlm.nih.gov/pubmed/27957320
http://dx.doi.org/10.1186/s13569-016-0061-3
Descripción
Sumario:BACKGROUND: Aggressive fibromatosis (AF), also known as desmoid tumor, is an uncommon soft tissue neoplasm. AF does not metastasize, but it is locally invasive and its propensity for recurrence after conservative resection is well documented. No effective cytotoxic treatment has been reported, hence there is a need for novel treatment strategies. CASE PRESENTATION: We present the case of an AF successfully treated with an oral tyrosine kinase inhibitor, pazopanib, with mild side effects. As far as we know, this is the first case of AF with complete response to pazopanib. CONCLUSION: Pazopanib might be an effective treatment option for AF.

Ejemplares similares